EGFR and adenocarcinoma: Current guidelines recommend testing all patients with metastatic NSCLC adenocarcinomas for the presence of activating EGFR mutations; in addition, these guidelines suggest the use of EGFR-TKIs as first-line therapy in patients with adenocarcinoma and a known EGFR mutation (17).